SCHEMBL29326571

SCHEMBL29326571

COc1ccc(-c2nnc(N[C@@H]3CCOC[C@H]3O)nc2C)c(O)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 3/20 0.37
SYK P43405 3/20 0.36
MAPK3 P27361 1/20 0.36
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
CDK4 P11802 6/20 0.35
CCND1 P24385 6/20 0.35
CCND3 P30281 6/20 0.35
CDK6 Q00534 6/20 0.35
MAPT P10636 2/20 0.35
TP53 P04637 1/20 0.35
TSHR P16473 1/20 0.35
HTT P42858 1/20 0.35
MAPK10 P53779 1/20 0.35
PTK2B Q14289 1/20 0.35
NCOA1 Q15788 1/20 0.35
NCOA3 Q9Y6Q9 1/20 0.35
NLRP3 Q96P20 2/20 0.35
KCNH2 Q12809 1/20 0.35
HPGDS O60760 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29326460 0.89 IL1B (0.44) CDK4CCND1CCND3CDK6NLRP3
SCHEMBL29326535 0.88 CDK4 (0.38) CDK4CCND1CCND3CDK6NLRP3
SCHEMBL29326455 0.86 CDK4 (0.40) CDK4CCND1CCND3CDK6NLRP3
SCHEMBL29975874 0.86 CDK4 (0.40) CDK4CCND1CCND3CDK6NLRP3
SCHEMBL29326566 0.86 NLRP3 (0.48) MAPK1SYKMEN1KMT2AMAPT
SCHEMBL29326626 0.85 NLRP3 (0.39) SYKCDK4CCND1CCND3CDK6
Hydrochloric Acid SCHEMBL30684819 0.85 NLRP3 (0.47) MAPK1SYKMEN1KMT2AMAPT
SCHEMBL29326381 0.83 NLRP3 (0.53) CDK4CCND1CCND3CDK6NLRP3
SCHEMBL29326748 0.77 CDK4 (0.37) SYKCDK4CCND1CCND3CDK6
SCHEMBL31130766 0.76 NLRP3 (0.41) SYKCDK4CCND1CCND3CDK6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239758-A1 SUBSTITUTED TRIAZINE COMPOUND NICO THERAPEUTICS, INC. 2024-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239758-A1 SUBSTITUTED TRIAZINE COMPOUND NLRP3, NLRP1, PYCARD MAPK1 2584/4885SYK 813/4885MAPK3 2913/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.